InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.62
(
0.02%
)
Bitcoin
62,645.56
(
3.07%
)
Post# of 252593
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 235228

Wednesday, 10/21/2020 4:46:39 PM

Wednesday, October 21, 2020 4:46:39 PM

Post# of 252593
Re: GSK’s RSV vaccines in development

…this is going to be a long multi year phase 3 program but the payoff could be huge on par w Shingrix….

It’s notable that GSK’s pediatric RSV vaccine is a year or two behind the maternal RSV vaccine; perhaps if the maternal vaccine attains strong market penetration, the pediatric vaccine (which is mostly for infants) will become superfluous, commercially.

p.s. MRNA is also working on an RSV vaccine or vaccines.

p.p.s. GSK’s RSV vaccine for older adults (age 60-80) uses the same adjuvant as Shingrix.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up